visual

Early Detection,

a way to protect your loved ones.

Early Detection?

It begins with CUBEBIO.

Intro video

scroll

About CUBEBIO

About
CUBEBIO

As a biomedical company specializing in cancer diagnosis, CUBEBIO is committed to global health improvements through early screening and detection of cancer. We are also a research-oriented company with competitive networking and marketing skills by forming mutually beneficial partnerships.

Research&Development

Research & Development

R&D

Unlike healthy cells, amino acid, glucose, nucleic acid precursor, protein, and other elements are metabolized in larger quantities and excreted in urine at different concentrations in the development of cancer. We can check the existence or non-existence of cancer by measuring these concentrations.

Partners

Partners

Introducing CUBEBIO’s partner. View More

Press Release

Press Release

2023-0921

[2023.09.21] CUBEBIO Co., Ltd. Attracts Investment of $46.7Mn through Technology Verification .. One step forward for US Market entry


CUBEBIO attended ‘CancerX Inaugural Member Summit 2023’, hosted in HHS(Health and Human Services) Mary E. Switzer Building, Washington D.C. on 7th of September. CancerX is a public-private partnership(PPP) appointed by the White House in attempt to accelerate CANCER MOONSHOT, the US Government initiative against cancer. Approximately 150 persons from more than 100 global businesses and the US Government Departments including ARPA-H(Advanced Research Projects Agency for Health) and the OASH (Office of the Assistant Secretary for Health) gathered to discuss business management and measures to reduce cancer mortality. (Picture by CUBEBIO) Expecting quantum leap following a series of favorable news, Ltd., a biomedical company specialized in the R&D and manufacture of IVD medical devices, attracted $46.7Mn investment. The $24.1Mn primal deposit was paid on 21st of September. CUBEBIO is reviewing a $98 million-worth investment and NASDAQ listing with an US corporation. The key factor of such large-scale investment is considered to be the successful clinical trial results on urine-based pancreatic cancer diagnosis conducted in joint research with SNUH(Seoul National University Bundang Hospital). Signing the joint technology development contract with SNUH last year, CUBEBIO proceeded pancreatic cancer as its primary research target among various screen-able cancer types using their technology. Pancreatic cancer is notorious for its extremely low 5-year survival rate of 13.9%. Despite the fact the only way to increase its survival rate is through early detection, the rate of early diagnosis in pancreatic cancer does not exceed 10%. The joint research team revealed that biomarkers in urine can screen pancreatic cancer at an early stage with high accuracy, which the related industries noted. On 4th of August, CUBEBIO signed to participate CANCER MOONSHOT, Biden Cabinet’s nation-wide initiative against cancer, in recognition of its advanced technology. The core of CANCER MOONSHOT is to introduce the recent technology in cancer diagnosis and treatment and to politically and financially support the related parties in an effort to reduce Americans’ death rate from cancer by 50% over the next 25 years. The US government is actively promoting the CANCER MOONSHOT, to the extent that President Biden has formed a separate cabinet (Cancer Cabinet). Cancer Moonshot is led by CancerX, a public-private partnership established by the U.S. government, and major members include Johnson & Johnson, AstraZeneca, Takeda Pharmaceutical, MD Anderson Cancer Center, Intel, and Amazon Web Services. On August 18th, an online meetup of CancerX members from many different countries including CUBEBIO was held. During the conference, plans for future operations such as reinforcing cooperation among cancer-related businesses were discussed along with the introduction of the first steering committee which consists of 12 global companies and institutions. On the 7th of this month, about 150 attendees participated in the ‘CancerX Inaugural Member Summit 2023’, which consists of hundreds of global agencies and businesses including CUBEBIO, at the HHS Mary E. Switzer Building, Washington D.C. with multiple US Government Department personnel. During the ‘CancerX Inaugural Member Summit 2023’, CUBEBIO is said to have spotlighted the significance of early cancer screening, drawing attention and support to the subject. Furthermore, the company had conversed with major cancer center authorities in the US, such as Memorial Sloan Kettering Cancer Center, City of Hope, and Moffitt Cancer Center, about introducing the urine-based cancer screening system to the US. Cooperation schemes were reviewed in regards to investment and US market debut with the related parties from Yosemite founded by Reed Jobs, son of Steve Jobs who died of pancreatic cancer, in attempt to invest in healthcare companies targeting cancer and Medical & IT specialized investor, Andreessen Horowitz, and more. According to CUBEBIO, it anticipates collaborating with global companies and professional institutions in the US and it has already begun discussing matters of investment, sales, manufacturing, and production with US corporations including CancerX members. The recent consensus to open ‘Cancer policy dialogue’ among the trilateral leaders (KOR, US, JPN) reflects the US Government’s elevated interest in the cancer industry. CUBEBIO entering the US market seems imminent regarding its partnerships with global corporations in addition to such interest. In addition to the Greater China market where the company is cooperating with the Hong Kong conglomerate, CUBEBIO is conducting joint research with domestic institutions in Japan, Singapore, and the Middle East. By overcoming the initial high entry barrier in collaboration with the local institutions, such business model is expected to promise a solid business structure within the domestic market. The foreign institutions such as the National Cancer Centre Singapore are conducting joint research with CUBEBIO. They anticipate CUBEBIO’s urine-based cancer screening to play a notable role in their local field of early detection and diagnosis of cancer. CUBEBIO is escalating to stably approach the MEDCs’ market via such collaboration with multiple overseas agencies. Meanwhile, in May 2023, CUBEBIO’s product was selected as an innovative product for the Scouter Demo Day hosted by the PPS (Public Procurement Service), a government agency of South Korea. The product will officially be listed as ‘PPS selected innovative product’ and the agency will bind a public agency sales contract using $38 million budget. CUBEBIO is a venture company whose product screens the presence of cancer by analyzing biomarkers within urine. The company holds 34 patents including the biosensor patent shared by Samsung Electronics. Two more patents are settled to be issued as a result of its consistent R&D. The company’s technology can be specified as ▲Convenient method of examination, ▲Frequent screening via non-invasive specimen, urine, ▲Screening multiple types of cancer in 1 test, and ▲Deriving results within 5 minutes.  Related article  Korea JoongAng Daily: https://www.joongang.co.kr/article/25194332  Seoul Shinmun: https://www.seoul.co.kr/news/newsView.php?id=20230921500172&wlog_tag3=naver  Chosun Biz: https://biz.chosun.com/science-chosun/bio/2023/09/21/24POEL7WRZE67ESEOCP4TCNBYA/?utm_source=naver&utm_medium=original&utm_campaign=biz ETNEWS: https://www.etnews.com/20230921000278 Medical Today: https://mdtoday.co.kr/news/view/1065602402955573 E2NEWS: http://www.e2news.com/news/articleView.html?idxno=301098 IT-BIZ: http://www.it-b.co.kr/news/articleView.html?idxno=70694 
2023-0519

[2023.05.19] CUBEBIO's urine-based cancer screening product selected as the 'Innovative product' in Scouter Demo-day run by Public Procurement Service(PPS)


전문심사위원, 국민평가단 심사. 공공서비스 현장에 쓰일 혁신제품 선발 ㈜큐브바이오는 동사의 소변기반 암 스크리닝 제품이 5월 8일 조달청 주최 ‘2023년 혁신제품 스카우터 데모데이’ 공개 선발대회에서 최종 합격하여 공공기관이 국내 첫 번째 구매자가 되는 기회에 다가서게 되었다. ▲ 이종욱 조달청장이 ‘스카우터 데모데이’에서 인사말을 하고 있다. 사진출처=조달청  조달청에서 시행하고 있는 혁신조달은 공공조달을 활용해 국내 기업의 혁신제품을 초기에 도입, 육성하여 글로벌 시장 진출 확대 및 세계시장을 선도하기 위한 제도로 ‘공공이 혁신제품을 선도적으로 구매해 기술혁신성장을 지원하고, 공공서비스 질을 개선’하는 정책이다. 이번 혁신제품을 뽑는 ‘데모데이’는 지난 4월 26~27일 이틀간 킨텍스에서 진행되었다. 예선을 통과해 본선 무대에 오른 미래차, 탄소중립, 환경 및 바이오 헬스 등 8개 분야의 기업들이 경연을 벌였으며 국민평가단 40명과 전문가 12명, 스카우터 11명으로 구성된 심사단의 심사를 거쳐 합격 제품이 결정되었다. 혁신제품으로 최종 등록되면 연 500억원에 가까운 조달청 시범구매예산을 통해 제품을 시범구매 하게 되며 3년간 공공기관과의 수의계약 혜택을 통한 판매 실적의 기회가 부여된다. 또한 전용몰인 혁신장터 등록 등 다양한 판로지원 혜택도 주어진다. 특히 공공구매기관은 전체 물품구매액 중 일부 자금을 혁신제품 구매에 사용하도록 되어 있고, 이러한 구매 실적을 매년 말 기관평가에 반영하고 있어 혁신제품은 공공구매 판로확대와 함께 공공기관 실적을 쌓을 수 있는 패스트트랙으로 평가받고 있다. ㈜큐브바이오의 소변기반 암 스크리닝 제품은 금번 조달청 혁신제품 스카우터 데모데이에서 선정됨에 따라 혁신제품 지정에 필요한 절차를 밟게 된다. 이후 혁신제품으로 최종 등록되면 3년간 공공기관과 한도 금액 없이 수의계약이 가능해지며, 정부가 최초로 제품을 구매하여 사용성 입증 및 레퍼런스를 확보하게 되면 국내시장 창출과 동시에 해외시장 판매확대로도 이어질 수 있다. 큐브바이오 관계자는 “최근 홍콩, 마카오, 대만, 동남아시아 등 8개국에 3년간 약 1,000억원 규모의 수출 계약을 체결하는 등 그 동안 수출을 통한 해외시장 개척에 주력했지만, 조달청 혁신제품으로 최종 등록되면 국내 공공기관으로의 판매와 함께 단기간 내에 실증사례 형성이 가능하다. 한국 공공기관에서의 사용은 국내 판로 개척뿐만 아니라 해외 공공기관 판매 및 실증으로도 이어질 수 있을 것”이라고 말했다.  한편 큐브바이오는 34건의 암 관련 특허를 보유한 바이오 전문기업으로 분당서울대학교병원 및 이화의료원과 소변기반 암 진단 관련 공동기술개발을 진행하며, 제품의 생산은 지난 3월 계약을 통해 GC녹십자메디스가 맡고 있다.     
2022-0217

[2022.02.17] CUBEBIO, selected as the new resident company at the Healthcare Innovation Park (HIP) of Seoul National University Hospital


체외진단 전문기업 큐브바이오가 16일 분당서울대학교병원 헬스케어혁신파크(HIP) 입주 기업으로 선정됐다. 분당서울대학교병원 헬스케어혁신파크(HIP) 입주 기업으로 선정된 큐브바이오는 소변으로 암을 진단하는 기술을 통해 암 진단의 새로운 지표를 제시할 것으로 평가 받는 기업으로 지난 1월 분당서울대학교병원, 이대목동병원, 이대서울병원, 기쁨병원 등과 공동기술개발계약을 체결하여 암 진단 기술의 한 단계 도약을 위한 발판을 마련하였다. 분당서울대학교병원 헬스케어혁신파크(HIP)는 의료기기, 헬스케어 ICT, 휴먼유전체, 나노의학, 재생의학 분야에 있어 산학연 주체간의 공동연구와 협업을 통해 첨단의료 구현을 위한 기술개발을 선도하는 헬스케어 융·복합 연구의 핵심 거점이다. 특히 대규모 임상시험 시설을 갖춘 병원이 지리적으로 연계되어 있어 연구개발, 동물실험, 임상시험 등을 한 곳에서 진행할 수 있으며 분당서울대학교병원이 빅데이터 센터 구축 사업, 국내 최대 인공지능(AI) 정밀의료 사업에 참여하는 등 K-바이오 혁신을 위해 적극 나서고 있어 입주 기업들과 다양한 시너지를 낼 수 있는 클러스터로 꼽힌다.   기사출처 데일리경제 : http://www.kdpress.co.kr/news/articleView.html?idxno=110720 관련기사 파이낸셜뉴스 : https://www.fnnews.com/news/202202171513406237 글로벌에픽 : http://www.globalepic.co.kr/view.php?ud=202202171540351556cf2d78c68_29
View More